{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:13Z","timestamp":1794017233639,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Inorganic Biochemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jinorgbio.2025.113183","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:01:54Z","timestamp":1765209714000},"page":"113183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Triple-action Pt(IV) prodrugs of cisplatin and oxaliplatin with indole propionate and 4-phenylbutyrate ligands as potent anticancer agents"],"prefix":"10.1016","volume":"276","author":[{"given":"Leila","family":"Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolda","family":"Romero-Canelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Erxleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinorgbio.2025.113183_bb0005","series-title":"SEER Cancer Statistics Review, 1975\u20132009","author":"Howlader","year":"2012"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","article-title":"Bevacizumab combined with platinum\u2013taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)","volume":"24","author":"Komiyama","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0015","first-page":"e733","article-title":"Impact of the localization of the primary tumor and RAS\/BRAF mutational status on maintenance strategies after first-line oxaliplatin, fluoropyrimidine, and bevacizumab in metastatic colorectal cancer: results from the AIO 0207 trial","volume":"17","author":"Noepel-Duennebacke","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.4291","article-title":"A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress","volume":"23","author":"Bruno","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0030","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejic.201601278","article-title":"Platinum(IV) prodrugs \u2013 a step closer to Ehrlich\u2019s vision?","volume":"2017","author":"Kenny","year":"2017","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0035","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1021\/jm070740j","article-title":"Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells","volume":"50","author":"Nemirovski","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0040","article-title":"Reactive cysteines in proteins are the dominant reductants for platinum(IV) prodrug activation in live cells","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0045","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8276139","article-title":"Current developments in Pt(IV) prodrugs conjugated with bioactive ligands","volume":"2018","author":"Li","year":"2018","journal-title":"Bioinorg. Chem. Appl."},{"issue":"4","key":"10.1016\/j.jinorgbio.2025.113183_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.chembiol.2004.03.024","article-title":"Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes","volume":"11","author":"Barnes","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215578","article-title":"Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands","volume":"501","author":"Starha","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ica.2023.121388","article-title":"An overview of recent advancements in anticancer Pt(IV) prodrugs: new smart drug combinations, activation and delivery strategies","volume":"548","author":"Marotta","year":"2023","journal-title":"Inorg. Chim. Acta"},{"issue":"6","key":"10.1016\/j.jinorgbio.2025.113183_bb0065","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1039\/D1DT03886A","article-title":"Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities","volume":"51","author":"Ravera","year":"2022","journal-title":"Dalton Trans."},{"issue":"1","key":"10.1016\/j.jinorgbio.2025.113183_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s41061-023-00448-3","article-title":"Pt(IV) complexes in the search for novel platinum prodrugs with promising activity","volume":"382","author":"Aher","year":"2024","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ceb.2013.01.001","article-title":"Targeting histone modifications-epigenetics in cancer","volume":"25","author":"Waldmann","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0080","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1096\/fj.14-250654","article-title":"Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators","volume":"28","author":"Yang","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0085","first-page":"23","article-title":"Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation","volume":"750","author":"Gong","year":"2013","journal-title":"Mutat. Res."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.20372","article-title":"Histone deacetylase inhibitors: understanding a new wave of anticancer agents","volume":"112","author":"Villar-Garea","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jinorgbio.2025.113183_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737140.2025.2458156","article-title":"Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy","volume":"25","author":"Shirbhate","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0100","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0105","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1039\/C7DT01054K","article-title":"Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(IV) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]","volume":"46","author":"Harper","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0110","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1002\/chem.201805626","article-title":"An anticancer PtIV prodrug that acts by mechanisms involving DNA damage and different epigenetic effects","volume":"25","author":"Kostrhunova","year":"2019","journal-title":"Chem. A Eur. J."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/pharmaceutics15020677","article-title":"Influence of the fatty acid metabolism on the mode of action of a cisplatin(IV) complex with phenylbutyrate as axial ligands","volume":"15","author":"Mendrina","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jinorgbio.2025.113183_bb0120","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s10637-024-01479-3","article-title":"Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models","volume":"42","author":"Begum","year":"2024","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111125","article-title":"Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780\/A2780cis cells","volume":"210","author":"Almotairy","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0130","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1039\/C9QI01453E","article-title":"A class of Pt(IV) triple-prodrugs targeting nucleic acids, thymidylate synthases and histone deacetylases","volume":"7","author":"Ding","year":"2020","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0135","doi-asserted-by":"crossref","first-page":"11180","DOI":"10.1039\/D1DT01421H","article-title":"ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug","volume":"50","author":"Li","year":"2021","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0140","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1039\/C8SC00428E","article-title":"Triple action Pt(IV) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance","volume":"9","author":"Petruzzella","year":"2018","journal-title":"Chem. Sci."},{"issue":"22","key":"10.1016\/j.jinorgbio.2025.113183_bb0145","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1021\/acs.jmedchem.0c01400","article-title":"Platinum(IV)-estramustine multiaction prodrugs are effective antiproliferative agents against prostate cancer cells","volume":"63","author":"Karmakar","year":"2020","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.jinorgbio.2025.113183_bb0150","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1039\/D0DT04135A","article-title":"Pt(IV) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity","volume":"50","author":"Gabano","year":"2021","journal-title":"Dalton Trans."},{"issue":"32","key":"10.1016\/j.jinorgbio.2025.113183_bb0155","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1039\/D3DT01876H","article-title":"Platinum(IV) combo prodrugs containing cyclohexane-1R,2R-diamine, valproic acid, and perillic acid as a multiaction chemotherapeutic platform for colon cancer","volume":"52","author":"Gabano","year":"2023","journal-title":"Dalton Trans."},{"issue":"44","key":"10.1016\/j.jinorgbio.2025.113183_bb0160","doi-asserted-by":"crossref","first-page":"17829","DOI":"10.1039\/D4DT01571A","article-title":"Multi-functional biotinylated platinum(IV)\u2013SAHA conjugate for tumor-targeted chemotherapy","volume":"53","author":"Gupta","year":"2024","journal-title":"Dalton Trans."},{"issue":"18","key":"10.1016\/j.jinorgbio.2025.113183_bb0165","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.1039\/D2DT00090C","article-title":"Multifunctional platinum(iv) complex bearing HDAC inhibitor and biotin moiety exhibits prominent cytotoxicity and tumor-targeting ability","volume":"51","author":"Han","year":"2022","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0170","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1002\/anie.201706739","article-title":"A quadruple-action platinum(IV) prodrug with anticancer activity against KRAS mutated cancer cell lines","volume":"56","author":"Petruzzella","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/srep29367","article-title":"Oxidative stress induced by Pt(IV) pro-drugs based on the cisplatin scaffold and indole carboxylic acids in axial position","volume":"6","author":"Tolan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ica.2019.04.038","article-title":"Cytotoxicity and ROS production of novel Pt(IV) oxaliplatin derivatives with indole propionic acid","volume":"492","author":"Tolan","year":"2019","journal-title":"Inorgan. Chim. Acta"},{"issue":"4","key":"10.1016\/j.jinorgbio.2025.113183_bb0185","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3390\/ijms25042181","article-title":"Platinum(IV) prodrugs incorporating an indole-based derivative, 5-benzyloxyindole-3-acetic acid in the axial position exhibit prominent anticancer activity","volume":"25","author":"Aputen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jinorgbio.2025.113183_bb0190","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1021\/acs.jmedchem.2c02036","article-title":"Novel indole\u2212chalcone derivative-ligated platinum(iv) prodrugs attenuate cisplatin resistance in lung cancer through ROS\/ER stress and mitochondrial dysfunction","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0195","first-page":"193","article-title":"Rapid method for the synthesis of cis-[Pt(NH3)2Cl2]","volume":"8","author":"Dhara","year":"1970","journal-title":"Indian J. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0200","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/jm00373a009","article-title":"Synthesis, characterization, and properties of a group of platinum(IV) complexes","volume":"27","author":"Brandon","year":"1984","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0205","series-title":"Process for Preparation of 1,2-Diamino-Cyclohexane-Platinum(II) Complexes","author":"Cid","year":"2014"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.scitotenv.2004.04.049","article-title":"Platinum emissions and levels in motorway dust samples: influence of traffic characteristics","volume":"334","author":"Ward","year":"2004","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0215","first-page":"3","article-title":"Determination of platinum group elements (PGE) in environmental samples by ICP-MS: a critical assessment of matrix separation for the mitigation of interferences","volume":"5","author":"Whitely","year":"2005","journal-title":"Geochem.: Explor., Environ., Anal."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","article-title":"Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin","volume":"24","author":"Morrison","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.microc.2015.03.016","article-title":"A simple, sensitive analytical method for platinum trace determination in human urine","volume":"122","author":"Alonso","year":"2015","journal-title":"Microchem. J."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0230","series-title":"Test No. 107: Partition Coefficient (n-Octanol\/Water): Shake Flask Method, Organisation for Economic Co-operation and Development","author":"OECD","year":"1995"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0235","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/s41598-017-03864-w","article-title":"Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates","volume":"7","author":"Novohradsky","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0240","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity and its relationship with passive drug permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0245","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0250","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0255","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-007-0756-2","article-title":"Mitochondria, oxidative stress and cell death","volume":"12","author":"Ott","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.106033","article-title":"Spheroids in cancer research: recent advances and opportunities","volume":"100","author":"Arora","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jinorgbio.2025.113183_bb0265","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12935-021-01853-8","article-title":"Challenges of applying multicellular tumor spheroids in preclinical phase","volume":"21","author":"Han","year":"2021","journal-title":"Cancer Cell Int."}],"container-title":["Journal of Inorganic Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013425003642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013425003642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:21:42Z","timestamp":1781511702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0162013425003642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0162013425003642"],"URL":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2025.113183","relation":{},"ISSN":["0162-0134"],"issn-type":[{"value":"0162-0134","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple-action Pt(IV) prodrugs of cisplatin and oxaliplatin with indole propionate and 4-phenylbutyrate ligands as potent anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Inorganic Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2025.113183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113183"}}